Auryxia

Auryxia Uses, Dosage, Side Effects, Food Interaction and all others data.

Hyperphosphatemia in chronic kidney disease on dialysis: Ferric iron binds dietary phosphate in the GI tract and precipitates as ferric phosphate. This compound is insoluble and is excreted in the stool. By binding phosphate in the GI tract and decreasing absorption, ferric citrate lowers the phosphate concentration in the serum.Iron deficiency anemia in chronic kidney disease not on dialysis: Ferric iron is reduced from the ferric to the ferrous form by ferric reductase in the GI tract. After transport through the enterocytes into the blood, oxidized ferric iron circulates bound to the plasma protein transferrin, and can be incorporated into hemoglobin.

Auryxia
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Auryxia
Generic	Ferric Citrate
Weight	210mg,
Type	Oral tablet
Therapeutic Class	Oral Iron preparations
Manufacturer
Available Country	United States,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Auryxia is a phosphate binder used for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. Auryxia is an iron replacement product used for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.
Pediatric Use: The safety and efficacy of Auryxia have not been established in pediatric patients.

Geriatric Use: Clinical studies of Auryxia included 292 subjects aged 65 years and older (104 subjects aged 75 years and older). Overall, the clinical study experience has not identified any obvious differences in responses between the elderly and younger patients in the tolerability or efficacy of Auryxia.

Dosage

Auryxia dosage

Hyperphosphatemia in chronic kidney disease on dialysis:

Starting dose is 2 tablets orally 3 times per day with meals.
Adjust dose by 1 to 2 tablets as needed to maintain serumphosphorus at target levels, up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.

Iron deficiency anemia in chronic kidney disease not on dialysis:

Starting dose is 1 tablet orally 3 times per day with meals.
Adjust dose as needed to achieve and maintain hemoglobin goal, up to a maximum of 12 tablets daily.

Side Effects

Most common adverse reactions (incidence ≥5%) are discolored feces, diarrhea, constipation, nausea, vomiting, cough, abdominal pain, and hyperkalemia.

Precaution

Iron absorption from Auryxia may lead to excessive elevations in iron stores. Increases in serum ferritin and transferrin saturation (TSAT) levels were observed in clinical trials. In a 56-week safety and efficacy trial evaluating the control of serum phosphate levels in patients with chronic kidney disease on dialysis in which concomitant use of intravenous iron was permitted, 55 (19%) of patients treated with Auryxia had a ferritin level >1500 ng/mL as compared with 13 (9%) of patients treated with active control. Assess iron parameters (e.g., serum ferritin and TSAT) prior to initiating Auryxia and monitor iron parameters while on therapy. Patients receiving intravenous iron may require a reduction in dose or discontinuation of intravenous iron therapy.

Interaction

When clinically significant drug interactions are expected, consider separation of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medication.

Pregnancy & Breastfeeding use

There are no available data on Auryxia use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. There are no human data regarding the effect of Auryxia in human milk, the effects on the breastfed child, or the effects on milk production.

Contraindication

Auryxia is contraindicated in patients with iron overload syndromes.

Acute Overdose

No data are available regarding overdose of Auryxia in patients. In patients with chronic kidney disease, the maximum dose studied was 2,520 mg ferric iron (12 tablets of Auryxia) per day. Iron absorption from Auryxia may lead to excessive elevations in iron stores, especially when concomitant intravenous iron is used.